Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

@chiefpd2 #AMRGBristol https://t.co/QwofchAD8c

RT @BMCParkinsons: #Research Monday -- The @chiefpd2 phase 3 trial design to test rivastigmine to reduce falls in #Parkinsons disease in 60…

RT @BMCParkinsons: #Research Monday -- The @chiefpd2 phase 3 trial design to test rivastigmine to reduce falls in #Parkinsons disease in 60…

#Research Monday -- The @chiefpd2 phase 3 trial design to test rivastigmine to reduce falls in #Parkinsons disease in 600 people with PD in the UK funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA): https://t.co/